Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

BACKGROUND: Ipilimumab improves the survival of metastatic melanoma patients. Despite documented, durable objective responses, a significant number of patients fails to benefit from treatment. The aim of this study was to identify an upfront marker for treatment benefit. METHODS: A total of 187 meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrucci, P F, Gandini, S, Battaglia, A, Alfieri, S, Di Giacomo, A M, Giannarelli, D, Cappellini, G C Antonini, De Galitiis, F, Marchetti, P, Amato, G, Lazzeri, A, Pala, L, Cocorocchio, E, Martinoli, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580390/
https://www.ncbi.nlm.nih.gov/pubmed/26010413
http://dx.doi.org/10.1038/bjc.2015.180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580390/
https://www.ncbi.nlm.nih.gov/pubmed/26010413
http://dx.doi.org/10.1038/bjc.2015.180

Ejemplares similares